Lamotrigine Therapy in Infantile Neuronal Ceroid Lipofuscinosis (INCL)

Laura Åberg; H. Heiskala; S.-L. Vanhanen; J. J. Himberg; G. Hosking; A. Yuen; P. Santavuori

doi:10.1055/s-2007-973676

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000041.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Neuropediatrics 1997; 28(1): 77-79
DOI: 10.1055/s-2007-973676

Short communications

Lamotrigine Therapy in Infantile Neuronal Ceroid Lipofuscinosis (INCL)

Laura Åberg¹ , H. Heiskala² , S.-L. Vanhanen¹ , J. J. Himberg¹ , G. Hosking³ , A. Yuen³ , P. Santavuori¹

¹Children's Hospital, Pediatric Neurology, University of Helsinki,
²Rinnekoti Foundation, Espoo
³Glaxo Wellcome

Further Information

Publication History

Publication Date:
13 March 2007 (online)

Also available at

PDF Download Buy Article Permissions and Reprints

Abstract

Since 1990, altogether 16 INCL patients received lamotrigine (LTG) because of intractable epilepsy. The response to LTC was favorable in 15/16 children. The severity of seizures decreased significantly in 15/16 patients, the frequency of seizures decreased in 14/16, and the effects were maintained. In addition, LTC had a beneficial effect on the wellbeing of 14/16 children. LTC failed to maintain it's efficacy in monotherapy. No severe side effects were found.

Key words

Infantile neuronal ceroid lipofuscinosis - Lamotrigine - Epilepsy